Loading organizations...
§ Private Profile · Cambridge, United Kingdom
Biotech company developing novel T-cell enhancing therapeutics using its proprietary Humabody platform for immuno-oncology.
Crescendo Biologics is a Cambridge, United Kingdom-based biotechnology company that develops novel T-cell enhancing therapeutics for immuno-oncology applications using its proprietary Humabody platform of antibody-like molecules. The firm focuses on creating simplified, multi-functional treatments designed for the selective activation of tumor-specific T cells within the tumor microenvironment, advancing clinical assets such as its lead candidate CB307. Operating as a private venture-backed entity, the enterprise has successfully secured $140.42 million in total funding through its Series C stage and currently maintains an intellectual property portfolio of 36 filed patents. The organization's executive leadership and board of directors have featured notable industry figures over its lifecycle, including current chief executive officer Theodora Harold, former CEO Peter Pack, and Non-Executive Chairman Kevin Johnson. Crescendo Biologics was originally spun out from the Babraham Institute and formally founded in 2009 by Mike Romanos.
Crescendo Biologics has raised $140.9M across 5 funding rounds.
Crescendo Biologics has raised $140.9M in total across 5 funding rounds.
Crescendo Biologics has raised $140.9M across 5 funding rounds. Most recently, it raised $32.0M Other Equity in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 24, 2023 | $32M Venture Round | — | Andera Partners, Sonia Benhamida, Quan Capital, Sofinnova Partners, Takeda | Announced |
| Apr 1, 2018 | $70M Series B | Gilles Nobécourt | Soffinova Partners, EMBL Ventures, Marietta WU, Takeda Ventures | Announced |
| Apr 3, 2014 | $3.3M Series A Plus | Imperial Innovations | Astellas Venture Management, EMBL Ventures, Sofinnova Partners | Announced |
| Dec 17, 2013 | $28.4M Series A | ROB Woodman | Astellas Venture Management, Sofinnova Partners | Announced |
| Oct 12, 2009 | $7.2M Seed | Sofinnova Partners | Aitua, Avlar BioVentures, Rainbow Seed Fund | Announced |
Crescendo Biologics has raised $140.9M in total across 5 funding rounds.
Crescendo Biologics's investors include Andera Partners, Sonia Benhamida, Quan Capital, Sofinnova Partners, Takeda, Gilles Nobécourt, Soffinova Partners, EMBL Ventures, Marietta Wu, Takeda Ventures, Imperial Innovations, Astellas Venture Management.
Crescendo Biologics is a privately-held, clinical-stage biotechnology company developing novel, targeted T cell enhancing therapeutics for immuno-oncology.[1][3][4] It leverages a rapid discovery process and fully human VH domain-based Humabodies to create immune cell enhancing drugs, addressing unmet needs in cancer treatment by boosting T cell activity.[3][5] The company serves patients with solid tumors and other cancers, solving the problem of insufficient immune response through precise, differentiated biologics; it remains active with recent accounts to December 2024, indicating ongoing operations and growth momentum in biotech R&D.[2]
Crescendo Biologics was incorporated on 13 November 2007 as Translocus Limited, a UK private limited company focused on biotechnology research (SIC 72110).[2] It rebranded to Crescendo Biologics on 16 March 2009, shifting emphasis to immuno-oncology therapeutics based on antibody fragment technology.[2][5] Headquartered in Cambridge, England, the company emerged from early innovation in Humabody VH domains, achieving clinical-stage status through pivotal advancements in T cell enhancement, with steady filing history reflecting sustained development.[1][2][3]
Crescendo Biologics rides the immuno-oncology wave, capitalizing on surging demand for T cell therapies amid advances in precision medicine and biologics.[1][3][4] Timing aligns with post-2020 clinical successes in checkpoint inhibitors and CAR-T, where antibody fragments like Humabodies offer advantages in tumor penetration and modularity.[5] Favorable market forces include biotech funding resurgence and regulatory nods for novel modalities, positioning Cambridge's biotech cluster as a hub; the company influences the ecosystem by advancing VH domain tech, potentially enabling partnerships and licensing in the $100B+ oncology market.[1][2]
Next steps likely involve advancing clinical trials for lead T cell enhancers, with accounts due in 2026 signaling pipeline maturation.[2] Trends like bispecific antibodies and AI-driven discovery will shape progress, amplifying Humabody scalability. Influence may evolve through acquisitions or alliances, solidifying its role in next-gen immuno-oncology—echoing its origins as a targeted innovator tackling cancer's immune evasion.[3][4]